Sample prompts by information source
AskMED.ai™ is an advanced data analysis tool that combines national healthcare encounter data, proprietary predictive models, medical publications, news reports, and user loaded documents (private to the user).
Use this resource to get started unlocking comprehensive insights into healthcare trends using a conversational interface.
Need help getting started?
First select the source you would like to query. Then you can copy the single prompts listed below and paste them into the AskMED.ai chat interface. Feel free to substitute the diseases, conditions, medications, and topics as needed.
National claims dataset
National claims data set consists of diagnosis, procedure and medication data. Time range from 2020-10-01 to 2023-09-30, last three years of data.
National Claims Dataset
Example Prompts
- How many people in the national claims dataset have a diagnosis of type 2 diabetes mellitus?
- How many people in the National claims dataset have “elevated blood glucose level” or “type 2 diabetes mellitus”?
- How many people have malaise and fatigue and taking atorvastatin calcium?
- How many men in Texas have a diagnosis of “essential (primary) hypertension”?
- How many cases of Merkel cell carcinoma are in the National claims dataset during 2021 year?
- In our National claims dataset how many people with a diagnosis of “type 2 diabetes mellitus” are taking metformin?
- From the national claims dataset build a table that shows the number of patients with a diagnosis of amyloidosis by month and year in chronological order. Please use the name for the month, not the number of the month. Please place the months in the rows, and the years in the columns.
Published Papers
PubMed Publications
Example Prompts
- What are the factors that lead to misdiagnosis and lack of diagnosis for amyloidosis-related peripheral neuropathy and what is the estimated time to diagnosis from first symptoms?
- What are the clinical and economic consequences for lack of diagnosis for amyloidosis-related peripheral neuropathy?
- What emerging evidence would you highlight to convince skeptical researchers of the prognostic and predictive utility of tumor mutational burden?
- What is the overall response rate and the median duration of response for Carvykti in multiple myeloma?
- Summarize the differences between Opdivo and Keytruda in terms of response rates, progression-free survival, and overall survival for NSCLC.
My Uploaded Documents
Query uploaded documents
Example Prompts
- What are the factors that lead to misdiagnosis and lack of diagnosis for amyloidosis-related peripheral neuropathy and what is the estimated time to diagnosis from first symptoms?
- What are the clinical and economic consequences for lack of diagnosis for amyloidosis-related peripheral neuropathy?
- What emerging evidence would you highlight to convince skeptical researchers of the prognostic and predictive utility of tumor mutational burden?
- What is the overall response rate and the median duration of response for Carvykti in multiple myeloma?
- Summarize the differences between Opdivo and Keytruda in terms of response rates, progression-free survival, and overall survival for NSCLC.